Activation of the MAP kinase pathway induces apoptosis in the merkel cell carcinoma cell line UISO

Journal of Investigative Dermatology

Volumn 127, Issue 9, 2007, Pages 2116-2122

  Houben, Roland ^a,b   Ortmann, Sonja ^a,b   Schrama, David ^a   Herold, Marco J ^a   Berberich, Ingolf ^a   Reichardt, Holger M ^a   Becker, Juergen C ^a,b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; BENZYLOXYCARBONYLVALYLALANYLASPARTYL FLUOROMETHYL KETONE; ESTROGEN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N [5 (3 DIMETHYLAMINOBENZAMIDO) 2 METHYLPHENYL] 4 HYDROXYBENZAMIDE; RAF PROTEIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL STRAIN UISO; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MERKEL CELL TUMOR; PRIORITY JOURNAL; RARE DISEASE; SIGNAL TRANSDUCTION; SKIN CANCER; SKIN CARCINOGENESIS; STRESS FIBER; TREATMENT PLANNING;

ACTINS; APOPTOSIS; CARCINOMA, MERKEL CELL; CELL LINE, TUMOR; DNA; ENZYME ACTIVATION; ENZYME INHIBITORS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-RAF; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 34547903251     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/sj.jid.5700857     Document Type: Article

References (35)

1. Baccarini M (2002) An old kinase on a new path: Raf and apoptosis. Cell Death Differ 9:783-5
2. Baumann B, Weber CK, Troppmair J, Whiteside S, Israel A, Rapp UR et al. (2000) Raf induces NF-kappa B by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation. Proc Natl Acad Sci USA 97:4615-20
3. Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49:4682-9
4. Cagnol S, Obberghen-Schilling E, Chambard JC (2006) Prolonged activation of ERK1,2 induces FADD-independent caspase 8 activation and cell death. Apoptosis 11:337-46
5. Daum G, Eisenmann-Tappe I, Fries HW, Troppmair J, Rapp UR (1994) The ins and outs of Raf kinases. Trends Biochem Sci 19:474-80
6. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-54
7. Ellis CA, Clark G (2000) The importance of being K-Ras. Cell Signal 12:425-34
8. Gotz R, Wiese S, Takayama S, Camarero GC, Rossoll W, Schweizer U et al. (2005) Bag1 is essential for differentiation and survival of hematopoietic and neuronal cells. Nat Neurosci 8:1169-78
9. Hall A (1998) Rho GTPases and the actin cytoskeleton. Science 279:509-14
10. Hall-Jackson CA, Eyers PA, Cohen P, Goedert M, Boyle FT, Hewitt N et al. (1999) Paradoxical activation of Raf by a novel Raf inhibitor. Chem Biol 6:559-68
11. Houben R, Michel B, Vetter-Kauczok CS, Pfohler C, Laetsch B, Wolter MD et al. (2006) Absence of classical MAP kinase pathway signaling in Merkel cell carcinoma. J Invest Dermatol 126:1135-42
12. Kerkhoff E, Houben R, Loffler S, Troppmair J, Lee JE, Rapp UR (1998) v Regulation of c-myc expression by Ras/Raf signaling. Oncogene 16:211-6
13. Kerkhoff E, Leberfinger CB, Schmidt G, Aktories K, Rapp UR (2002) Diverse effects of RacV12 on cell transformation by Raf: partial inhibition of morphological transformation versus deregulation of cell cycle control. Biochim Biophys Acta Mol Cell Res 1589:151-9
14. Kerkhoff E, Rapp UR (1997) Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1. Mol Cell Biol 17:2576-86
15. Kunnimalaiyaan M, Chen H (2006b) The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs 17:139-42
16. Kunnimalaiyaan M, Chen H (2006a) The Raf-1 pathway: a molecular target for treatment of select neuroendocrine tumors? Anticancer Drugs 17:139-42
17. Kuss AW, Knodel M, Berberich-Siebelt F, Lindemann D, Schimpl A, Berberich I (1999) A1 expression is stimulated by CD40 in B cells and rescues WEHI 231 cells from anti-IgM-induced cell death. Eur J Immunol 29:3077-88
18. Mercer KE, Pritchard CA (2003) Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim Biophys Acta 1653:25-40
19. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, Van der Horst CM et al. (2005) BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436:720-4
20. Miller RW, Rabkin CS (1999) Merkel cell carcinoma and melanoma: etiological similarities and differences. Cancer Epidemiol Biomarkers Prev 8:153-8
21. Naumann U, Eisenmann-Tappe I, Rapp UR (1997) The role of Raf kinases in development and growth of tumors. Recent Results Cancer Res 143:237-44
22. O'Neill E, Rushworth L, Baccarini M, Kolch W (2004) Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1. Science 306:2267-70
23. Pearson G, Bumeister R, Henry DO, Cobb MH, White MA (2000) Uncoupling Raf1 from MEK1/2 impairs only a subset of cellular responses to Raf activation. J Biol Chem 275:37303-6
24. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM et al. (2003) High frequency of BRAF mutations in nevi. Nat Genet 33:19-20
25. Popp S, Waltering S, Herbst C, Moll I, Boukamp P (2002) UV-B-type mutations and chromosomal imbalances indicate common pathways for the development of Merkel and skin squamous cell carcinomas. Int J Cancer 99:352-60
26. Poulsen M (2004) Merkel-cell carcinoma of the skin. Lancet Oncol 5: 593-9
27. Rajalingam K, Wunder C, Brinkmann V, Churin Y, Hekman M, Sievers C et al. (2005) Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nat Cell Biol 7:837-43
28. Ridley AJ, Hall A (1992) The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell 70:389-99
29. Ronan SG, Green AD, Shilkaitis A, Huang TS, Das Gupta TK (1993) Merkel cell carcinoma: in vitro and in vivo characteristics of a new cell line. J Am Acad Dermatol 29:715-22
30. Sahai E, Olson MF, Marshall CJ (2001) Cross-talk between Ras and Rho signaling pathways in transformation favours proliferation and increased motility. EMBO J 20:755-66
31. Thompson N, Lyons J (2005) Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery. Curr Opin Pharmacol 5:350-6
32. Tsai FM, Shyu RY, Jiang SY (2006) RIG1 inhibits the Ras/mitogen-activated protein kinase pathway by suppressing the activation of Ras. Cell Signal 18:349-58
33. Wang HG, Rapp UR, Reed JC (1996) Bcl-2 targets the protein kinase Raf-1 to mitochondria. Cell 87:629-38
34. Worda M, Sreevidya CS, Ananthaswamy HN, Cerroni L, Kerl H, Wolf P (2005) T1796A BRAF mutation is absent in Merkel cell carcinoma. Br J Dermatol 153:229-32
35. Zhong J, Troppmair J, Rapp UR (2001) Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria. Oncogene 20:4807-16